This WIREs title offers downloadable PowerPoint presentations of figures for non-profit,
educational use, provided the content is not modified and full credit is given to the author
and publication.
References 1 Singal, R, Ginder, GD. DNA methylation. Blood 1999, 93: 4059–4070.et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448: 714–717.et al. Methyl‐CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003, 22: 6335–6345.et al. Polycomb‐mediated methylation on Lys27 of histone H3 pre‐marks genes for de novo methylation in cancer. Nat Genet 2007, 39: 232–236.et al. Frequent deletions and down‐regulation of micro‐ RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99: 15524–15529.et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101: 2999–3004.et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 67: 1424–1429.et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435: 834–838.et al. Antisense transcription in the mammalian transcriptome. Science 2005, 309: 1564–1566.et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008, 451: 202–206.et al. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 2003, 34: 157–165.et al. Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J Biol Chem 2004, 279: 37175–37184.et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl. 12 ): 40–61.et al. DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004, 100: 2598–2606.et al. Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 2001, 15: 157–165.et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001, 98: 244–246.et al. DNA methylation changes in multiple myeloma. Leukemia 2004, 18: 1687–1692.et al. Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinical‐biological features of multiple myeloma. Ann Hematol 2006, 85: 474–477.et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007, 109: 1228–1232.et al. p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett 2005, 222: 247–254.et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002, 118: 1034–1040.Jr. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007, 109: 1337–1338.et al. Frequent death‐associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001, 7: 1724–1729.et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 2005, 24: 732–736.et al. High‐frequency promoter hypermethylation of the deleted in liver cancer‐1 gene in multiple myeloma. J Clin Pathol 2006, 59: 947–951.et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol 2005, 75: 505–510.et al. Down‐regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 2007, 67: 5328–5336.et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 2006, 108: 3881–3889.et al. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 2005, 92: 1165–1172.et al. Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin‐6‐responsive multiple myeloma KAS‐6/1 cells. J Biol Chem 2005, 280: 4182–4187.et al. Epigenetic silencing of manganese superoxide dismutase (SOD‐2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. Cancer Biol Ther 2005, 4: 585–592.et al. Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 2006, 27: 197–204.et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004, 104: 3697–3704.et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005, 65: 4673–4682.et al. 5‐Azacytidine, a DNA methyltransferase inhibitor, induces ATR‐mediated DNA double‐strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007, 6: 1718–1727.et al. Genome‐wide transcriptional response to 5‐aza‐2′‐deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 2008, 68: 44–54.et al. Phase 1 study of low‐dose prolonged exposure schedules of the hypomethylating agent 5‐aza‐2′‐deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103: 1635–1640.et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 2008, 3: e1882.et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114: 3448–3458.et al. Microarray analysis of epigenetic silencing of gene expression in the KAS‐6/1 multiple myeloma cell line. Cancer Res 2004, 64: 3465–3473.et al. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Genome Res 2009, 19: 1593–1605.et al. Chromosome‐wide and promoter‐specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005, 37: 853–862.et al. Comprehensive high‐throughput arrays for relative methylation (CHARM). Genome Res 2008, 18: 780–790.et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 2006, 16: 1046–1055.et al. Genome‐wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T‐lymphoid features. Blood 2009, 113: 2795–2804.et al. Targeted and genome‐scale strategies reveal gene‐body methylation signatures in human cells. Nat Biotechnol 2009, 27: 361–368.et al. Meta‐analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter‐platform data integration. PLoS One 2008, 3: e2965.
.jpg)
